Equities

V3V

DE000A0BL849

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 11:36:10 2024-04-26 am EDT			5-day change	1st Jan Change
5.15 ^EUR	+6.40%		+15.99%	-1.72%

2023	VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	VITA 34 AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

NVR: Vita 34 AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

December 07, 2023 at 09:30 am EST

EQS Total Voting Rights Announcement: Vita 34 AG / Total Voting Rights Announcement
Vita 34 AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

07.12.2023 / 15:28 CET/CEST
Total Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of total number of voting rights

1. Details of issuer

Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany

2. Type of capital measure

	Type of capital measure	Date of status / date of effect
	Conditional capital increase (Sec. 41 para. 2 WpHG)
X	Other capital measure (Sec. 41 para. 1 WpHG)	07 Dec 2023

3. New total number of voting rights:

17640104

07.12.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Vita 34 AG
	Deutscher Platz 5a
	04103 Leipzig
	Germany
Internet:	www.vita34.de


End of News	EQS News Service

1792403 07.12.2023 CET/CEST

Latest news about VITA 34 AG

VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
VITA 34 AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Vita 34 Starts Patient Enrollment in Phase 1 Trial of CAR-T Drug Candidate	23-05-12	MT
Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug Candidate	23-05-12	CI
VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-30	CI
VITA 34 AG Provides Revenue Guidance for the Financial Year 2023	23-04-25	CI
VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
VITA 34 AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-30	CI
VITA 34 AG Revises Earnings Guidance for the Financial Year 2022	22-08-29	CI
VITA 34 AG Announces Dirk Plaga Will Accordingly Assume the Position of Chief Financial Officer of the Company	22-06-29	CI
VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-31	CI
VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-30	CI
Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022	22-04-29	CI
Vita 34 Names New Chair, Appoints Chief Commercial Officer	22-03-21	MT
Vita 34 AG Announces Change in the Chair of the Management Board	22-03-18	CI
VITA 34 AG completed the acquisition of Polski Bank Komórek Macierzystych S.A from from AOC Health GmbH, Jakub Baran, Tomasz Baran and others.	21-11-14	CI
VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
Vita 34 AG Announces Withdrawal of Guidance for Financial Year 2021	21-11-09	CI
Vita 34 : Commences Offer Period for Polski Bank Komorek Takeover	21-09-20	MT
VITA 34 AG Affirms Earnings Guidance for the Full Fiscal Year 2021	21-08-31	CI
VITA 34 AG Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
Vita 34 : Names New CFO	21-08-16	MT
VITA 34 AG Announces Chief Financial Officer Changes	21-08-16	CI
VITA 34 AG Provides Earnings Guidance for the Year 2021	21-05-31	CI

Chart VITA 34 AG

Duration

Period

More charts

Company Profile

Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the childâs birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.

Sector

Healthcare Facilities & Services

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for VITA 34 AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.15 EUR

Average target price

5.3 EUR

Spread / Average Target

+2.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
VITA 34 AG	-1.72%	95.84M
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
PURE HEALTH HOLDING	-31.75%	11.77B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
DAVITA INC.	+27.44%	11.71B

Other Healthcare Facilities & Services